PRINCIPIA BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN SANOFI’S PHASE 2B TRIAL OF SAR442168 IN MULTIPLE SCLEROSIS, TRIGGERING $30 MILLION MILESTONE SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) — Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage...
HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH A MESOTHELIN-TARGETING T CELL ENGAGER (HPN536) IN PHASE 1/2A CLINICAL TRIAL FOR OVARIAN AND OTHER SOLID TUMOR CANCERS HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial...
PDS Biotechnology Completes Merger with Edge Therapeutics Shares of Combined Company to Commence Trading on Nasdaq Capital Market under New Symbol “PDSB” on March 18, 2019 PRINCETON, N.J., March 18, 2019 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (“PDS...
Neurana Pharmaceuticals Announces First Patient Enrolled in the STAR Study Neurana Pharmaceuticals Announces First Patient Enrolled in the “STAR Study,” a Phase 2 Dose Ranging Study of Tolperisone in Acute Muscle Spasms of the Back SAN DIEGO, February 4th, 2019...
PRINCIPIA BIOPHARMA ANNOUNCES POSITIVE DATA FROM PHASE 2 PEMPHIGUS VULGARIS TRIAL AT 2019 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING IN LATE-BREAKING PRESENTATION Reached primary endpoint of Control of Disease Activity at four weeks in 54 percent of patients on...
HARPOON THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Harpoon Therapeutics, Inc. (“Harpoon”), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today the...
Recent Comments